Log in to your Inderes Free account to see all free content on this page.
Bavarian Nordic
189.10 DKK
-1.66 %
Less than 1K followers
BAVA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-1.66 %
-0.63 %
-5.45 %
-0.92 %
-21.79 %
+30.32 %
-0.71 %
-33.60 %
+32.58 %
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Read moreMarket cap
14.98B DKK
Turnover
10.59M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
13.5.
2026
Interim report Q1'26
21.8.
2026
Interim report Q2'26
13.11.
2026
Interim report Q3'26
All
Research
Webcasts
Press releases
ShowingAll content types
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio